CAPE has been reported as a potential regulator of oncogenic molecular pathways to inhibit cell proliferation in vitro or tumor growth in vivo in animal models of various carcinoma cells including melanoma, cholangiocarcinoma, breast, lung, colon, pancreas, and prostate carcinoma cells [7,8,9,10,11,12,13]. This evidence concerns the gene SMC2 and carcinoma.